Lorenza Rimassa is Associate Professor of Medical Oncology, member of the Residency Program Directors Coordinating Committee, member of the Executive Committee and Academic Board of the PhD Program in Applied Clinical Research at Humanitas University and Head of Hepatopancreatobiliary Oncology at IRCCS Humanitas Research Hospital, in Rozzano (Milan), Italy.
She is Treasurer, member of the Executive Committee and Governing Board of the International Liver Cancer Association (ILCA), Chair of the EORTC Hepatopancreatobiliary and Neuroendocrine Tumors Task Force, holds the position of Special Expert – International Trials Europe on the Hepatobiliary Task Force of the National Cancer Institute (NCI, US), member of the Management Committee of the COST Action CA22125 Precision medicine in biliary tract cancer” (Precision-BTC-Network), and member of the Scientific Committee of the Swiss Liver Cancer Foundation.
She is co-chair of the Technical Commission of the Lombardy Oncology Network on liver and biliary tract cancer in collaboration with the Hepatogastroenterology Network (Italy), and member of the Group of Experts – Strategic Committee for the National Guideline System (SNLG), Italian Ministry of Health – Italian National Institute of Health (ISS) – DM 624712343.
She has a long-standing interest in the field of clinical and translational research for gastrointestinal cancers. She is principal investigator and member of the steering committee, data monitoring committee for national and international, phase 1–3 clinical and translational trials of new drugs and biomarkers for hepatocellular carcinoma and cholangiocarcinoma/biliary tract cancer. She is speaker, chair, discussant, and member of the organizing and scientific committee at national and international congresses.
She has authored more than 200 articles on the development of new treatments and biomarkers for hepatobiliary cancer. She is an author of the ESMO Guideline on Biliary Tract Cancer, a member of the Italian Inter-Society Guideline Writing Committee on Hepatocellular Carcinoma, of ESMO, ASCO, EASL, ILCA, and AIOM. She is Associate Editor for Journal of Hepatology, Section Editor-in-Chief for the Disease Biomarker Section of Journal of Personalized Medicine, and an editorial board member of several journals including JHEP Reports, Liver International, Therapeutic Advances in Medical Oncology, Cancers, and Journal of Hepatocellular Carcinoma.
